Literature DB >> 22318764

Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity.

Andrew D Patterson1, Yatrik M Shah, Tsutomu Matsubara, Kristopher W Krausz, Frank J Gonzalez.   

Abstract

Acetaminophen (APAP) overdose causes acute liver failure in humans and rodents due in part to the destruction of mitochondria as a result of increased oxidative stress followed by hepatocellular necrosis. Activation of the peroxisome proliferator-activated receptor alpha (PPARα), a member of the nuclear receptor superfamily that controls the expression of genes encoding peroxisomal and mitochondrial fatty acid β-oxidation enzymes, with the experimental ligand Wy-14,643 or the clinically used fibrate drug fenofibrate, fully protects mice from APAP-induced hepatotoxicity. PPARα-humanized mice were also protected, whereas Ppara-null mice were not, thus indicating that the protection extends to human PPARα and is PPARα-dependent. This protection is due in part to induction of the PPARα target gene encoding mitochondrial uncoupling protein 2 (UCP2). Forced overexpression of UCP2 protected wildtype mice against APAP-induced hepatotoxicity in the absence of PPARα activation. Ucp2-null mice, however, were sensitive to APAP-induced hepatotoxicity despite activation of PPARα with Wy-14,643. Protection against hepatotoxicity by UCP2-induction through activation of PPARα is associated with decreased APAP-induced c-jun and c-fos expression, decreased phosphorylation of JNK and c-jun, lower mitochondrial H(2)O(2) levels, increased mitochondrial glutathione in liver, and decreased levels of circulating fatty acyl-carnitines. These studies indicate that the PPARα target gene UCP2 protects against elevated reactive oxygen species generated during drug-induced hepatotoxicity and suggest that induction of UCP2 may also be a general mechanism for protection of mitochondria during fatty acid β-oxidation.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318764      PMCID: PMC3378765          DOI: 10.1002/hep.25645

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

Review 1.  The 'novel' 'uncoupling' proteins UCP2 and UCP3: what do they really do? Pros and cons for suggested functions.

Authors:  Jan Nedergaard; Barbara Cannon
Journal:  Exp Physiol       Date:  2003-01       Impact factor: 2.969

Review 2.  Paracetamol.

Authors:  P F D'Arcy
Journal:  Adverse Drug React Toxicol Rev       Date:  1997-03

3.  Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes.

Authors:  Teruyo Nakatani; Nobuyo Tsuboyama-Kasaoka; Mayumi Takahashi; Shinji Miura; Osamu Ezaki
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

4.  Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure.

Authors:  C Chen; G E Hennig; H E Whiteley; J C Corton; J E Manautou
Journal:  Toxicol Sci       Date:  2000-10       Impact factor: 4.849

5.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.

Authors:  J M Peters; R C Cattley; F J Gonzalez
Journal:  Carcinogenesis       Date:  1997-11       Impact factor: 4.944

6.  Mitochondrial uncoupling protein 2 structure determined by NMR molecular fragment searching.

Authors:  Marcelo J Berardi; William M Shih; Stephen C Harrison; James J Chou
Journal:  Nature       Date:  2011-07-24       Impact factor: 49.962

7.  Protection by clofibrate against acetaminophen hepatotoxicity in male CD-1 mice is associated with an early increase in biliary concentration of acetaminophen-glutathione adducts.

Authors:  J E Manautou; A Tveit; D J Hoivik; E A Khairallah; S D Cohen
Journal:  Toxicol Appl Pharmacol       Date:  1996-09       Impact factor: 4.219

8.  Clofibrate pretreatment diminishes acetaminophen's selective covalent binding and hepatotoxicity.

Authors:  J E Manautou; D J Hoivik; A Tveit; S G Hart; E A Khairallah; S D Cohen
Journal:  Toxicol Appl Pharmacol       Date:  1994-12       Impact factor: 4.219

Review 9.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  S Mandard; M Müller; S Kersten
Journal:  Cell Mol Life Sci       Date:  2004-02       Impact factor: 9.261

10.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.

Authors:  S S Lee; T Pineau; J Drago; E J Lee; J W Owens; D L Kroetz; P M Fernandez-Salguero; H Westphal; F J Gonzalez
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

View more
  54 in total

1.  Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells.

Authors:  Chad N Brocker; Jiang Yue; Donghwan Kim; Aijuan Qu; Jessica A Bonzo; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-01-12       Impact factor: 4.052

Review 2.  Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity.

Authors:  Frank J Gonzalez; Zhong-Ze Fang; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-04-02       Impact factor: 4.481

3.  Saikosaponin d protects against acetaminophen-induced hepatotoxicity by inhibiting NF-κB and STAT3 signaling.

Authors:  Aiming Liu; Naoki Tanaka; Lu Sun; Bin Guo; Jung-Hwan Kim; Kristopher W Krausz; Zhongze Fang; Changtao Jiang; Julin Yang; Frank J Gonzalez
Journal:  Chem Biol Interact       Date:  2014-09-27       Impact factor: 5.192

Review 4.  UCP2, a mitochondrial protein regulated at multiple levels.

Authors:  Massimo Donadelli; Ilaria Dando; Claudia Fiorini; Marta Palmieri
Journal:  Cell Mol Life Sci       Date:  2013-06-27       Impact factor: 9.261

5.  c9,t11-Conjugated linoleic acid ameliorates steatosis by modulating mitochondrial uncoupling and Nrf2 pathway.

Authors:  Maria Pina Mollica; Giovanna Trinchese; Gina Cavaliere; Chiara De Filippo; Ennio Cocca; Marcello Gaita; Antonio Della-Gatta; Angela Marano; Giuseppe Mazzarella; Paolo Bergamo
Journal:  J Lipid Res       Date:  2014-03-15       Impact factor: 5.922

6.  TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury.

Authors:  Tsutomu Matsubara; Naoki Tanaka; Misako Sato; Dong Wook Kang; Kristopher W Krausz; Kathleen C Flanders; Kazuo Ikeda; Hans Luecke; Lalage M Wakefield; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2012-10-03       Impact factor: 5.922

Review 7.  The role of hypoxia-inducible factors in metabolic diseases.

Authors:  Frank J Gonzalez; Cen Xie; Changtao Jiang
Journal:  Nat Rev Endocrinol       Date:  2018-12       Impact factor: 43.330

Review 8.  Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.

Authors:  Juan M Zolezzi; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

9.  The protection of glycyrrhetinic acid (GA) towards acetaminophen (APAP)-induced toxicity partially through fatty acids metabolic pathway.

Authors:  Hua Yang; Tingshu Jiang; Ping Li; Qishan Mao
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

10.  Identification and Characterization of Fenofibrate-Induced Liver Injury.

Authors:  Jawad Ahmad; Joseph A Odin; Paul H Hayashi; Naga Chalasani; Robert J Fontana; Huiman Barnhart; Elizabeth T Cirulli; David E Kleiner; Jay H Hoofnagle
Journal:  Dig Dis Sci       Date:  2017-11-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.